Results 31 to 40 of about 5,598,449 (384)

Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer. [PDF]

, 2016
A single early prostate-specific antigen (PSA) level has been correlated with a higher likelihood of prostate cancer diagnosis and death in younger men. PSA testing in older men has been considered of limited utility.
Karnes, R Jeffrey, Kattan, Michael W, MacKintosh, F Roy, Morrell, Christopher H, Nawaf, Cayce B, Neville, Thomas B, Rawson, Lori, Sprenkle, Preston C, Walter, Louise C   +8 more
core   +1 more source

The human gastrointestinal microbiota and prostate cancer development and treatment [PDF]

, 2020
The human gastrointestinal microbiome contains commensal bacteria and other microbiota that have been gaining increasing attention in the context of cancer development and response to treatment.
Alanee, Alexander, Althuis, Amirian, Arthur, Bostwick, Boursi, Buti, Cheng, Cimadamore, Cockburn, Costello, Cuevas-Ramos, Daniels, De Marzo, De Marzo, Dennis, Dominguez-Bello, Eckburg, Elkahwaji, Elkrief, Figueiredo, Gill, Golombos, Goodman, Graessler, Haller, Hamada, Hatakeyama, Hunter, Iida, Kamps, Lampe, Lara-Tejero, Lenoir, Liss, Masood, Meldrum, Miquel, Miyake, Montassier, Mosca, Mouraviev, Musso, Nakai, O'Hara, Olsson, Paulos, Plottel, Porter, Poutahidis, Punnen, Qin, Redman, Ridlon, Roberts, Roy, Russell, Sfanos, Siegel, Smith, Sokol, Sokol, Sonn, The Global Cancer Observatory, Tulstrup, Vande Voorde, Viaud, Vivarelli, Vétizou, Wilson   +70 more
core   +1 more source

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

New England Journal of Medicine, 2004
BACKGROUND Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival.
I. Tannock, R. de Wit, W. Berry, J. Horti, A. Płużańska, K. Chi, S. Oudard, C. Théodore, N. James, I. Turesson, M. Rosenthal, M. Eisenberger   +11 more
semanticscholar   +1 more source

Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea

BMC Cancer, 2018
Background For the expanding population of bladder cancer survivors in Korea, the development of subsequent cancers is a significant concern. Here, we provide the second primary cancer incidence rates and types in Korean patients with bladder cancer ...
Whi-An Kwon, Jae Young Joung, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won   +10 more
doaj   +1 more source

Hedgehog Signalling in Androgen Independent Prostate Cancer [PDF]

, 2008
Objectives: Androgen-deprivation therapy effectively shrinks hormone-naïve prostate cancer, both in the prostate and at sites of distant metastasis.
Bisson, Isabelle, Ktori, Elena, McFaul, Siobhan, Oliver, R. Tim D, Price, Anna M., Prowse, David M., Purkis, Patricia E., Shaw, Greg   +7 more
core   +1 more source

Increased survival with enzalutamide in prostate cancer after chemotherapy.

New England Journal of Medicine, 2012
BACKGROUND Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth.
H. Scher, K. Fizazi, F. Saad, M. Taplin, C. Sternberg, K. Miller, R. de Wit, P. Mulders, K. Chi, N. Shore, A. Armstrong, T. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J. Hainsworth, M. Hirmand, B. Selby, L. Seely, J. D. de Bono   +19 more
semanticscholar   +1 more source

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma

Genome Medicine, 2019
Background Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no effective targeted ...
Raunak Shrestha, Noushin Nabavi, Yen-Yi Lin, Fan Mo, Shawn Anderson, Stanislav Volik, Hans H. Adomat, Dong Lin, Hui Xue, Xin Dong, Robert Shukin, Robert H. Bell, Brian McConeghy, Anne Haegert, Sonal Brahmbhatt, Estelle Li, Htoo Zarni Oo, Antonio Hurtado-Coll, Ladan Fazli, Joshua Zhou, Yarrow McConnell, Andrea McCart, Andrew Lowy, Gregg B. Morin, Tianhui Chen, Mads Daugaard, S. Cenk Sahinalp, Faraz Hach, Stephane Le Bihan, Martin E. Gleave, Yuzhuo Wang, Andrew Churg, Colin C. Collins   +32 more
doaj   +1 more source

Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai city districts: a retrospective population-based cohort study, 2000-2009. [PDF]

, 2014
BackgroundProstate cancer is the fifth most common cancer affecting men of all ages in China, but robust surveillance data on its occurrence and outcome is lacking. The specific objective of this retrospective study was to analyze the longitudinal trends
Deng, Haiju, Hu, Yi, Rao, Jianyu, Xu, Biao, Yuan, Hong, Zhao, Qi   +5 more
core   +3 more sources

Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

BMC Cancer, 2018
Background Bleomycin, etoposide, and cisplatin (BEP) chemotherapy administered every 3 weeks for 4 cycles remains the standard first line treatment for patients with intermediate- and poor-risk metastatic germ cell tumours (GCTs).
Nicola J. Lawrence, Howard Chan, Guy Toner, Martin R. Stockler, Andrew Martin, Sonia Yip, Nicole Wong, Annie Yeung, Danish Mazhar, Farzana Pashankar, Lindsay Frazier, Ray McDermott, Roderick Walker, Hsiang Tan, Ian D. Davis, Peter Grimison, on behalf of ANZUP   +16 more
doaj   +1 more source

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

New England Journal of Medicine, 2010
BACKGROUND Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer.
P. Kantoff, C. Higano, N. Shore, E. Berger, E. Small, D. Penson, C. Redfern, A. Ferrari, R. Dreicer, R. Sims, Yi Xu, M. Frohlich, P. Schellhammer   +12 more
semanticscholar   +1 more source